Brief: Nuvasive's Thoracolumbar Interbody Portfolio Receives First Clearance In U.S For Treatment Of Sagittal Deformities
Nov 9 (Reuters) - NuVasive Inc NUVA.O :
* NUVASIVE'S THORACOLUMBAR INTERBODY PORTFOLIO RECEIVES
FIRST
CLEARANCE IN THE US FOR THE TREATMENT OF SAGITTAL DEFORMITIES
* NUVASIVE INC - CLEARANCE EXPANDS PORTFOLIO'S INDICATIONS,
TO NOW
MULTIPLE LEVELS, FOR TREATMENT OF SAGITTAL MALALIGNMENT
Source text for Eikon: ID:nPn3QgCrCa
Further company coverage: NUVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NuVasive
See all newsJackson Financial to join small-cap S&P 600; shares climb
NuVasive Inc reports results for the quarter ended in June - Earnings Summary
Brief: NuVasive Q2 Adjusted EPS USD 0.56 Vs. IBES Estimate USD 0.55
NuVasive Inc expected to post earnings of 55 cents a share - Earnings Preview
Brief: NuVasive Borrows $350 Mln In Revolving Loans Under 2020 Facility